SOURCE: Bausch + Lomb

Bausch + Lomb

March 24, 2011 16:01 ET

Bausch + Lomb Appoints David Mordaunt, Ph.D. as Vice President, Development and Research, Surgical

ROCHESTER, NY--(Marketwire - March 24, 2011) - Bausch + Lomb, the global eye health company, announces the appointment of David Mordaunt, Ph.D. as vice president, Development and Research, Bausch + Lomb Surgical.

In this position, Dr. Mordaunt will be a member of the Surgical senior leadership team and will be responsible for global strategies and execution of development and research programs for the full portfolio of products. This includes equipment used for cataract and vitroretinal procedures, intraocular lenses including Crystalens®, which is the only FDA-approved accommodating intraocular lens offering a full range of natural vision, viscoelastics and new technologies focused on enhancing ophthalmologists ability to offer patient-centric procedures.

"I'm thrilled to be joining Bausch + Lomb Surgical," said Dr. Mordaunt. "They have a strong pipeline for innovative new technologies focused on improving ophthalmic surgical outcomes, which enhance patient vision and quality of life. I look forward to collaborating with the ophthalmic physician community to continue to advance Bausch + Lomb's product portfolio."

"Dr. Mordaunt's proven leadership in the development of transformational new product technologies in ophthalmology is well known," said Robert Grant, CEO and president, Bausch + Lomb Surgical. "We look forward to his experience and leadership in advancing products to benefit the physician and patient community we serve."

Dr. Mordaunt is a recognized expert in the medical device industry for the development of innovative technologies that have changed the standard of patient care. These technologies include Pattern Scanning Laser (PASCAL) for diabetic retinopathy, Selective Laser Trabeculoplasty (SLT) for glaucoma and Photodynamic Therapy (PDT) for macular degeneration.

Dr. Mordaunt has held positions of director, surgical R&D for Coherent, Inc.; vice president of R&D for Lumenis; and chief executive officer, president and co-founder of OPTIMEDICA Corp., which focuses on the treatment of diabetic retinopathy, glaucoma and cataract diseases. Most recently, Dr. Mordaunt was chief executive officer of Precision Light, which developed the foundation technologies for 4D imaging and evidenced-based outcome simulation in plastic surgery.

Dr. Mordaunt holds a bachelor of science and a doctorate degree in chemical physics, physics and chemistry from the University of Bristol, England. He was also awarded prestigious fellowships and held positions at the Max-Plank Institute in Gottingen, Germany, and the University of California at Berkeley.

Dr. Mordaunt will be based in Aliso Viejo, California. 

About Bausch + Lomb
Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at

Crystalens is a registered trademark of Bausch & Lomb.

Contact Information

  • News Media Contacts:
    Elizabeth Harness Murphy
    Director, Corporate Communications and Public Affairs
    Bausch + Lomb
    +1 585-281-8219 (mobile)

    Elisabeth Sandoval
    Vice President, Global Marketing - Surgical
    +1 949-389-1798 (office)